Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Magic mushroom compound shows promise for Tough-to-Treat depression and BPD

NCT ID NCT05399498

Symptom relief Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small Phase 2 trial tested a single 25mg dose of psilocybin in 9 adults with both major depressive disorder and borderline personality disorder. Researchers measured changes in depression and BPD symptoms over time. The goal was to see if psilocybin is safe and could help ease symptoms in this complex group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
psilocybin (a psychedelic compound)
What this could lead to
If it works, this could point toward a new treatment option for people with both depression and borderline personality disorder.
What could go wrong
This is a very small, early-stage trial with only 9 participants, so results may not apply to everyone. Psychedelic therapy can cause intense emotional experiences and is not without risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

9 people

The number who actually took part.

Started

Nov 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-65 * Diagnosed with current major depressive disorder * Montgomery-Asberg Depression Rating Scale (MADRS) score of \> 20 * Diagnosed with borderline personality disorder * Borderline Personality Disorder Symptom Assessment Scale (BPD-SAS) score of \> 20 * Ability to understand and sign the consent form Exclusion Criteria: * Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination * Current pregnancy or lactation, or inadequate contraception in women of childbearing potential * Illegal substance use based on urine toxicology screening (except cannabis use) * Current or past history of bipolar I disorder, schizophrenia, or schizoaffective disorder * Active substance use disorder

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Borderline personality disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

borderline personality disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Borderline personality disorder Major depressive disorder

Contacts and locations

Locations

  • University of Chicago

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.